Alterations of the gut microbiota associated with the occurrence and progression of viral hepatitis.

16s ribosomal RNA gene amplicon sequencing gut microbiota liver disease microbial markers viral hepatitis

Journal

Frontiers in cellular and infection microbiology
ISSN: 2235-2988
Titre abrégé: Front Cell Infect Microbiol
Pays: Switzerland
ID NLM: 101585359

Informations de publication

Date de publication:
2023
Historique:
received: 09 12 2022
accepted: 22 05 2023
medline: 23 6 2023
pubmed: 21 6 2023
entrez: 21 6 2023
Statut: epublish

Résumé

Gut microbiota is the largest population of microorganisms and is closely related to health. Many studies have explored changes in gut microbiota in viral hepatitis. However, the correlation between gut microbiota and the occurrence and progression of viral hepatitis has not been fully clarified. PubMed and BioProject databases were searched for studies about viral hepatitis disease and 16S rRNA gene sequencing of gut microbiota up to January 2023. With bioinformatics analyses, we explored changes in microbial diversity of viral hepatitis, screened out crucial bacteria and microbial functions related to viral hepatitis, and identified the potential microbial markers for predicting risks for the occurrence and progression of viral hepatitis based on ROC analysis. Of the 1389 records identified, 13 studies met the inclusion criteria, with 950 individuals including 656 patient samples (HBV, This study demonstrated comprehensively the gut microbiota characteristics in viral hepatitis, screened out crucial microbial functions related to viral hepatitis, and identified the potential microbial markers for predicting the risk of viral hepatitis.

Sections du résumé

Background
Gut microbiota is the largest population of microorganisms and is closely related to health. Many studies have explored changes in gut microbiota in viral hepatitis. However, the correlation between gut microbiota and the occurrence and progression of viral hepatitis has not been fully clarified.
Methods
PubMed and BioProject databases were searched for studies about viral hepatitis disease and 16S rRNA gene sequencing of gut microbiota up to January 2023. With bioinformatics analyses, we explored changes in microbial diversity of viral hepatitis, screened out crucial bacteria and microbial functions related to viral hepatitis, and identified the potential microbial markers for predicting risks for the occurrence and progression of viral hepatitis based on ROC analysis.
Results
Of the 1389 records identified, 13 studies met the inclusion criteria, with 950 individuals including 656 patient samples (HBV,
Conclusions
This study demonstrated comprehensively the gut microbiota characteristics in viral hepatitis, screened out crucial microbial functions related to viral hepatitis, and identified the potential microbial markers for predicting the risk of viral hepatitis.

Identifiants

pubmed: 37342245
doi: 10.3389/fcimb.2023.1119875
pmc: PMC10277638
doi:

Substances chimiques

RNA, Ribosomal, 16S 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1119875

Informations de copyright

Copyright © 2023 Yang, Mai, Zhou, Li, Wang, Lan, Lu, Yang, Guo, Ye, Cui, Liang and Huang.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Adv Sci (Weinh). 2020 Sep 02;7(20):2001936
pubmed: 33101877
J Gastroenterol Hepatol. 2022 Mar;37(3):518-530
pubmed: 34907602
Genome Med. 2020 Nov 23;12(1):102
pubmed: 33225985
Eur J Pharmacol. 2011 Sep;668 Suppl 1:S50-8
pubmed: 21816146
Pharmacol Biochem Behav. 2019 Jan;176:93-100
pubmed: 30528936
Front Immunol. 2022 Sep 23;13:972503
pubmed: 36211350
World J Gastroenterol. 2017 May 28;23(20):3589-3606
pubmed: 28611512
Gut Pathog. 2016 Sep 13;8(1):42
pubmed: 27625705
Curr Opin Immunol. 2021 Jun;70:7-14
pubmed: 33418116
World J Gastroenterol. 2021 Sep 7;27(33):5488-5501
pubmed: 34588747
Nutrients. 2019 Jul 25;11(8):
pubmed: 31349604
ACS Infect Dis. 2021 May 14;7(5):1059-1068
pubmed: 33119247
Biology (Basel). 2014 Dec 15;3(4):892-921
pubmed: 25517881
Front Microbiol. 2022 Jun 06;13:916061
pubmed: 35733959
Nutrients. 2019 Dec 06;11(12):
pubmed: 31817726
Nat Commun. 2017 Jul 25;8(1):125
pubmed: 28743900
Front Microbiol. 2019 Jun 25;10:1458
pubmed: 31293562
Nat Methods. 2016 Jul;13(7):581-3
pubmed: 27214047
Microbiome. 2017 Mar 3;5(1):27
pubmed: 28253908
JAMA Psychiatry. 2021 Dec 1;78(12):1343-1354
pubmed: 34524405
Chem Senses. 2020 Apr 17;45(3):187-194
pubmed: 31993633
Nat Biotechnol. 2019 Oct;37(10):1217-1228
pubmed: 31477923
J Immunol Res. 2018 Jul 25;2018:2361963
pubmed: 30148173
Int J Tryptophan Res. 2015 Aug 04;8:41-8
pubmed: 26309411
Ann Transl Med. 2022 May;10(10):549
pubmed: 35722392
mSystems. 2020 Oct 13;5(5):
pubmed: 33051377
Cells. 2018 Oct 12;7(10):
pubmed: 30322028
J Viral Hepat. 2020 Nov;27(11):1243-1252
pubmed: 32500937
Nat Microbiol. 2023 Jan;8(1):12-27
pubmed: 36522461
Microorganisms. 2019 Jan 10;7(1):
pubmed: 30634578
Front Microbiol. 2020 Mar 20;11:383
pubmed: 32265857
Brain Commun. 2021 Jun 01;3(2):fcab113
pubmed: 34704023
Gut Pathog. 2019 Jan 18;11:1
pubmed: 30675188
FEBS J. 2014 May;281(9):2228-39
pubmed: 24612645
Front Immunol. 2023 Mar 15;14:1137025
pubmed: 37006257
J Viral Hepat. 2022 Feb;29(2):94-106
pubmed: 34415656
Ann Hepatol. 2023 Jul-Aug;28(4):101109
pubmed: 37100384
Neoplasia. 2021 May;23(5):529-538
pubmed: 33945993
Cell Immunol. 2018 Apr;326:52-59
pubmed: 28860007
Cell Mol Immunol. 2021 Apr;18(4):866-877
pubmed: 33707689
Anim Nutr. 2020 Dec;6(4):421-428
pubmed: 33364458
Mucosal Immunol. 2021 Jan;14(1):113-124
pubmed: 32433514
J Nutr. 2020 May 1;150(5):1313-1323
pubmed: 32027752
Sci Rep. 2019 Nov 19;9(1):17109
pubmed: 31745234
Int J Syst Evol Microbiol. 2014 Oct;64(Pt 10):3526-3531
pubmed: 25052396
Hepatol Int. 2022 Oct;16(5):1208-1219
pubmed: 35972640
Front Cell Infect Microbiol. 2021 Apr 06;11:573923
pubmed: 33889550
Curr Protoc Bioinformatics. 2020 Jun;70(1):e100
pubmed: 32343490
Microbiome. 2018 May 17;6(1):90
pubmed: 29773078
Front Physiol. 2018 May 01;9:470
pubmed: 29780327
Gut Pathog. 2021 Oct 30;13(1):65
pubmed: 34717727
Front Microbiol. 2017 Nov 13;8:2222
pubmed: 29180991
PeerJ. 2018 Aug 8;6:e5364
pubmed: 30123705
Front Microbiol. 2019 Oct 23;10:2407
pubmed: 31708888
World J Gastroenterol. 2020 Oct 7;26(37):5543-5560
pubmed: 33071523
World J Clin Cases. 2018 Nov 6;6(13):589-599
pubmed: 30430114
Pathogens. 2021 Oct 22;10(11):
pubmed: 34832522
Cancer Med. 2020 Jun;9(12):4232-4250
pubmed: 32281295

Auteurs

Xing Yang (X)

School of Public Health, Guangxi Medical University, Nanning, China.
Guangxi Key Laboratory of AIDS Prevention and Treatment, Guangxi Universities Key Laboratory of Prevention and Control of Highly Prevalent Disease, Guangxi Medical University, Nanning, China.

Huanzhuo Mai (H)

School of Public Health, Guangxi Medical University, Nanning, China.
Guangxi Key Laboratory of AIDS Prevention and Treatment, Guangxi Universities Key Laboratory of Prevention and Control of Highly Prevalent Disease, Guangxi Medical University, Nanning, China.

Jie Zhou (J)

School of Public Health, Guangxi Medical University, Nanning, China.
Guangxi Key Laboratory of AIDS Prevention and Treatment, Guangxi Universities Key Laboratory of Prevention and Control of Highly Prevalent Disease, Guangxi Medical University, Nanning, China.

Zhuoxin Li (Z)

School of Public Health, Guangxi Medical University, Nanning, China.
Guangxi Key Laboratory of AIDS Prevention and Treatment, Guangxi Universities Key Laboratory of Prevention and Control of Highly Prevalent Disease, Guangxi Medical University, Nanning, China.

Qing Wang (Q)

School of Public Health, Guangxi Medical University, Nanning, China.
Guangxi Key Laboratory of AIDS Prevention and Treatment, Guangxi Universities Key Laboratory of Prevention and Control of Highly Prevalent Disease, Guangxi Medical University, Nanning, China.

Liuyan Lan (L)

School of Public Health, Guangxi Medical University, Nanning, China.
Guangxi Key Laboratory of AIDS Prevention and Treatment, Guangxi Universities Key Laboratory of Prevention and Control of Highly Prevalent Disease, Guangxi Medical University, Nanning, China.

Fang Lu (F)

School of Public Health, Guangxi Medical University, Nanning, China.
Guangxi Key Laboratory of AIDS Prevention and Treatment, Guangxi Universities Key Laboratory of Prevention and Control of Highly Prevalent Disease, Guangxi Medical University, Nanning, China.

Xiping Yang (X)

School of Public Health, Guangxi Medical University, Nanning, China.
Guangxi Key Laboratory of AIDS Prevention and Treatment, Guangxi Universities Key Laboratory of Prevention and Control of Highly Prevalent Disease, Guangxi Medical University, Nanning, China.

Baodong Guo (B)

School of Public Health, Guangxi Medical University, Nanning, China.
Guangxi Key Laboratory of AIDS Prevention and Treatment, Guangxi Universities Key Laboratory of Prevention and Control of Highly Prevalent Disease, Guangxi Medical University, Nanning, China.

Li Ye (L)

School of Public Health, Guangxi Medical University, Nanning, China.
Guangxi Key Laboratory of AIDS Prevention and Treatment, Guangxi Universities Key Laboratory of Prevention and Control of Highly Prevalent Disease, Guangxi Medical University, Nanning, China.

Ping Cui (P)

Guangxi Key Laboratory of AIDS Prevention and Treatment, Guangxi Universities Key Laboratory of Prevention and Control of Highly Prevalent Disease, Guangxi Medical University, Nanning, China.
Life Science Institute, Guangxi Medical University, Nanning, China.
Collaborative Innovation Centre of Regenerative Medicine and Medical BioResource Development and Application Co-constructed by the Province and Ministry, Guangxi Medical University, Nanning, China.

Hao Liang (H)

School of Public Health, Guangxi Medical University, Nanning, China.
Guangxi Key Laboratory of AIDS Prevention and Treatment, Guangxi Universities Key Laboratory of Prevention and Control of Highly Prevalent Disease, Guangxi Medical University, Nanning, China.
Life Science Institute, Guangxi Medical University, Nanning, China.
Collaborative Innovation Centre of Regenerative Medicine and Medical BioResource Development and Application Co-constructed by the Province and Ministry, Guangxi Medical University, Nanning, China.

Jiegang Huang (J)

School of Public Health, Guangxi Medical University, Nanning, China.
Guangxi Key Laboratory of AIDS Prevention and Treatment, Guangxi Universities Key Laboratory of Prevention and Control of Highly Prevalent Disease, Guangxi Medical University, Nanning, China.
Guangxi Colleges and Universities Key Laboratory of Prevention and Control of Highly Prevalent Diseases, Guangxi Medical University, Nanning, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH